Daijiworld Media Network – Moscow

Moscow, Sep 9: Russia has announced that it is ready to roll out Enteromix, a personalised cancer vaccine developed using advanced mRNA technology similar to COVID-19 vaccines. The breakthrough treatment, created by the National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology, has shown promising clinical trial results and could soon be available free of cost to patients.

Enteromix is designed to match each patient’s unique RNA profile, enabling doctors to customise doses that directly target the genetic features of tumor cells. Unlike chemotherapy or radiation, which harm healthy cells, the vaccine trains the immune system to recognise and destroy cancer cells, reducing side effects and improving patient tolerance.

According to Russia’s Federal Medical and Biological Agency (FMBA) head Veronika Skvortsova, initial clinical trials with 48 patients showed tumor shrinkage of 60% to 80%, halted tumor growth, and improved survival rates — all without severe side effects. The vaccine also works through repeated administrations, offering hope for long-term cancer management.

The first version of Enteromix targets colorectal cancer, one of the leading causes of cancer-related deaths worldwide, with additional versions under development for glioblastoma brain cancer and melanoma.

Russia showcased the vaccine at the 10th Eastern Economic Forum in Vladivostok, drawing international attention from delegates across 75 countries. Officials said the government will provide Enteromix free to patients once it receives full regulatory clearance.

Globally, several biotech giants, including BioNTech and Moderna, are also developing personalised mRNA cancer vaccines for different cancers, but Russia’s Enteromix stands out for claiming clinical readiness.

Experts say if approved, Enteromix could transform cancer treatment, offering patients safer, targeted therapies with fewer adverse effects and improved quality of life.